Quadramet (samarium [153Sm] lexidronam pentasodium)
- Region
- 🇪🇺 EU
- Active substance
- samarium [153Sm] lexidronam pentasodium
- Company
- CIS bio international
- Status
- Authorised
- Therapeutic area
- Pain; Cancer
- EU approval
- Wed 04 Feb 1998
- Application
- EMEA/H/C/000150
- ATC
- V10BX02
- Official record
- www.ema.europa.eu
Indication
Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan. The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Quadramet
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.